Welcome to our dedicated page for ARTIVION SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Artivion, Inc. (AORT) reported an insider Form 4. The Chief Commercial Officer sold 6,563 shares of common stock at $45.858 on 11/13/2025 (Transaction code: S). According to the footnote, the shares were sold upon RSU vesting to cover tax withholding via a “sell to cover” and do not represent a discretionary transaction.
After the sale, the reporting person beneficially owned 198,842 shares, held directly.
Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.
Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.
Artivion, Inc. (AORT) insider transaction: SVP and General Counsel Jean F. Holloway reported the sale of 5,761 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon the vesting of restricted stock units to pay tax withholding obligations via a “sell to cover” and “does not represent a discretionary transaction.”
Following the sale, the reporting person beneficially owns 163,408 shares directly. This Form 4 reflects an administrative tax-related sale rather than an open‑market discretionary trade.
Artivion (AORT) insider transaction: Officer Marshall Stanton reported a sell-to-cover of 4,993 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding obligations and did not represent a discretionary transaction.
Following the transaction, Stanton beneficially owns 56,641 shares directly. His role is listed as SVP, Clinical & MD Affair, and the filing was made by one reporting person.
AORT: A holder filed a Form 144 notice to sell 6,393 shares of common stock through Fidelity Brokerage Services, with an aggregate market value $285,575.31. The filing lists an approximate sale date of 11/14/2025 on the NYSE. Shares outstanding were 47,374,939.
The shares to be sold were acquired on 11/14/2025 via an option originally granted on 03/05/2019, with payment noted as cash. The filing also reports past 3‑month sales by John E. Davis: 3,373 shares on 11/10/2025 for $150,499.55 and 6,563 shares on 11/13/2025 for $300,968.02.
AORT received a Form 144 notice covering a proposed sale of 3,482 common shares. The filing lists an aggregate market value of $159,678.60, with an approximate sale date of 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired via restricted stock vesting on 11/10/2025 and 11/11/2025 in two equal tranches of 1,741 shares each, characterized as compensation. The filing also reports that Amy D. Horton sold 1,789 shares on 11/11/2025 for $79,823.21 in gross proceeds. Shares outstanding are listed as 47,374,939.
AORT filed a Form 144 notice for a proposed sale under Rule 144 by security holder Jean F. Holloway. The filing lists 5,761 shares of common stock to be sold, with an aggregate market value of $264,189.66, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025. Shares outstanding are shown as 47,374,939.
The shares to be sold were acquired via restricted stock vesting: 2,880 shares on 11/10/2025 and 2,881 shares on 11/11/2025, labeled as compensation. In the past three months, the filer reported sales of 10,000 shares on 08/25/2025 for $443,700.00, 2,960 shares on 11/10/2025 for $132,071.94, and 10,000 shares on 11/11/2025 for $461,800.00.
AORT disclosed a Form 144 notice for a proposed sale of 34,210 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $1,568,812.44. The filing lists an approximate sale date of 11/13/2025 on the NYSE.
The shares derive from recent restricted stock vesting: 17,105 shares on 11/10/2025 and 17,105 shares on 11/11/2025, each marked as Compensation. A recent activity section shows sales in the last three months by James Mackin of 12,500 shares on 08/15/2025 for $528,991.00 and 17,580 shares on 11/11/2025 for $784,400.26. Shares outstanding were 47,374,939 at the time referenced in the filing.
AORT filed a Form 144 for a proposed sale of up to 4,993 common shares, with an aggregate market value of $228,970.50. The approximate sale date is 11/13/2025, through Fidelity Brokerage Services LLC, on the NYSE.
The shares were acquired via restricted stock vesting as compensation: 2,496 shares on 11/10/2025 and 2,497 shares on 11/11/2025. In the past three months, the seller reported sales of 18,200 shares on 08/27/2025 for $801,211.32 and 2,566 shares on 11/11/2025 for $114,492.10. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being offered.
John E. Davis filed a Form 144 notice to sell up to 6,563 shares of common stock, with an aggregate market value of $300,968.02. The shares are slated for sale on or after 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired via restricted stock vesting from the issuer on 11/10/2025 (3,282 shares) and 11/11/2025 (3,281 shares), recorded as compensation. The filing also lists a recent sale by the same person on 11/11/2025 of 3,373 shares for gross proceeds of $150,499.55. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being sold.